Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 10, 2011, Pages 1527-1535

  Takkenberg, Bart ^a   Terpstra, Valeska ^a   Zaaijer, Hans ^a   Weegink, Christine ^a   Dijkgraaf, Marcel ^a   Jansen, Peter ^a   Beld, Marcel ^b   Reesink, Hendrik ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

Antiviral therapy; Clinicalhepatology; Hepatitis B virus; Interferon; Pegylated interferon; Virology

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CIRCULAR DNA; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTRAHEPATIC HEPATITIS B VIRUS DNA; PEGINTERFERON ALPHA2A; TOTAL INTRAHEPATIC COVALENTLY CLOSED CIRCULAR DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SEROCONVERSION; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80053118707     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06766.x     Document Type: Article

References (25)

1. World Health Organization. The world health report 1997. Geneva, Switzerland: World Health Organization, 1997.
2. Newbold JE, Xin H, Tencza M etal. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol. 1995; 69: 3350-7.
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 2000; 64: 51-68.
4. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-60.
5. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 2009; 51: 581-92.
6. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996; 2: 1104-8.
7. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-95.
8. Marcellin P, Lau GK, Bonino F etal. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004; 351: 1206-17.
9. Janssen HL, van Zonneveld M, Senturk H etal. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
10. Cooksley WG, Piratvisuth T, Lee SD etal. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 2003; 10: 298-305.
11. Wursthorn K, Lutgehetmann M, Dandri M etal. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
12. Chan HL, Wong VW, Tse AM etal. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 2007; 5: 1462-8.
13. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
14. Rijckborst V, Hansen BE, Cakaloglu Y etal. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
16. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
17. Boom R, Sol CJ, Heijtink R, Wertheim-van Dillen PM, van der Noorda J. Rapid purification of hepatitis B virus DNA from serum. J. Clin. Microbiol. 1991; 29: 1804-11.
18. Boom R, Sol C, Weel J, Gerrits Y, de Boer M, Wertheim-van DP. A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence. J. Clin. Microbiol. 1999; 37: 1489-97.
19. Werle-Lapostolle B, Bowden S, Locarnini S etal. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
20. Takkenberg RB, Zaaijer HL, Molenkamp R etal. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. J. Med. Virol. 2009; 81: 988-95.
21. Liu Y, Hussain M, Wong S, Fung SK, Yim HJ, Lok AS. A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J. Clin. Microbiol. 2007; 45: 553-8.
22. Saxena R, Zucker SD, Crawford JM. Anatomy and physiology of the liver. In: Zakim D, Boyer TD, eds. Hepatology; A Textbook of Liver Disease, Vol. 1. Philadelphia, PA: Elsevier Science, 2003; 3-30.
23. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir. Ther. 2006; 11: 909-16.
24. Sung JJ, Wong ML, Bowden S etal. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-7.
25. Zhu YY, Dong J, Chen Y-T, Chen J, Jiang J-D. Extending the treatment duration of peginterferon alfa-2a therapy to 72weeks increases the rate of HBeAg seroconversion in patients with HBeAg positive chronic hepatitis B. J. Hepatol. 2009; 50: S331-2.